Boleas-Aguirre Maria Soledad, Sánchez-Ferrandiz Noelia, Guillén-Grima Francisco, Perez Nicolas
Department of Otorhinolaryngology, Clínica Universitaria de Navarra, University Hospital and Medical School, University of Navarra, Navarra, Spain.
Laryngoscope. 2007 Aug;117(8):1474-81. doi: 10.1097/MLG.0b013e318065aa27.
The main objective of this study was to characterize the residual vestibular symptoms and disability in patients with Ménière's disease who had achieved complete control of vertigo through intratympanic gentamicin treatment. Furthermore, we assessed whether the Functional Level Score prior to treatment reflected the posttreatment symptoms and disability.
Prospective.
Tertiary medical center.
This study involved 103 patients with Ménière's disease treated with intratympanic gentamicin who, after a long-term follow up, have not suffered new vertigo spells and were not subject to any major modification in their treatment.
At inclusion and at the last follow-up visit after a minimum of 3 years of ending the treatment, the clinical status (number of vertigo spells), the unsteadiness as well as the disability produced by the disease, symptoms of anxiety, and compensation were asked using specific questionnaires. The results before and after treatment were analyzed using nonparametric tests.
After a 5-year follow-up, complete control of vertigo was obtained in 81% of the patients with Ménière's disease who were treated with intratympanic gentamicin. Of them, 15.5% still complained of unsteadiness. A functional level of 6 or unsteadiness after treatment are related with a nonreduction in disability after long-term control of vertigo spells.
The efficacy of gentamicin administered intratympanically is high after long-term follow-up as shown by the disappearance of vertigo spells and by the reduction in disability, increase in perception of quality of life, and reduction in anxiety related to vestibular symptoms. Unsteadiness, although an infrequent complaint, determines a level of almost similar severity in those issues. Special care must be taken with patients with a Functional Level Scale score of 6 at the time of beginning treatment.
本研究的主要目的是描述经鼓室内注射庆大霉素实现眩晕完全控制的梅尼埃病患者的残余前庭症状和功能障碍。此外,我们评估了治疗前的功能水平评分是否能反映治疗后的症状和功能障碍。
前瞻性研究。
三级医疗中心。
本研究纳入了103例接受鼓室内注射庆大霉素治疗的梅尼埃病患者,经过长期随访,这些患者未出现新的眩晕发作,且治疗未发生任何重大改变。
在入组时以及治疗结束至少3年后的最后一次随访时,使用特定问卷询问临床状况(眩晕发作次数)、不稳感以及疾病导致的功能障碍、焦虑症状和代偿情况。使用非参数检验分析治疗前后的结果。
经过5年随访,81%接受鼓室内注射庆大霉素治疗的梅尼埃病患者实现了眩晕的完全控制。其中,15.5%的患者仍抱怨有不稳感。治疗后功能水平为6或存在不稳感与眩晕发作长期得到控制后功能障碍未减轻有关。
长期随访显示,鼓室内注射庆大霉素疗效显著,眩晕发作消失,功能障碍减轻,生活质量感知提高,前庭症状相关焦虑减轻。不稳感虽不常见,但在这些问题上所确定的严重程度几乎相似。对于治疗开始时功能水平量表评分为6的患者必须给予特别关注。